Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGET: Tucatinib in HER2+ Breast Cancer with Brain Metastases
NCT05323955Phase 2Active, not recruiting
- Sponsor
- Carey Anders
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in breast cancer, sponsored by Carey Anders. Started Mar 2023; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05323955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323955.